Galderma's phase III trial showed nemolizumab significantly improved atopic dermatitis symptoms in 1,728 patients.
Galderma's phase III ARCADIA trials demonstrated significant improvements in atopic dermatitis patients with nemolizumab, a first-in-class monoclonal antibody targeting IL-31 receptor alpha. Nemolizumab, given every four weeks, showed greater results compared to placebo in combination with topical corticosteroids, with or without topical calcineurin inhibitors. The treatment improved skin lesions, itch and sleep disturbances in 1,728 participants.
July 25, 2024
4 Articles